(Q46135488)

English

Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris

scientific article published on 17 September 2008

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

quality control

0 references

Plasmodium falciparum

1 reference

based on heuristic

inferred from title

Pichia pastoris

object named as

Pichia pastoris

1 reference

based on heuristic

inferred from title

1

object named as

Bart W Faber

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

Edmond J Remarque

2

object named as

Edmond J Remarque

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

3

object named as

Clemens H M Kocken

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

11

object named as

Alan W Thomas

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

author name string

Pascale Cheront

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Doriano Cingolani

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Florence Xhonneux

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Margarita Jurado

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Michele Haumont

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Soren Jepsen

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Odile Leroy

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

language of work or name

0 references

publication date

17 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

26

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

48

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

6143-6150

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

The economic impact of malaria in Africa: a critical review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

A model to simulate the impact of timing, coverage and transmission intensity on the effectiveness of indoor residual spraying (IRS) for malaria control.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Insecticide-treated nets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Drug-resistant malaria - an insight

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Apical membrane antigen 1: a malaria vaccine candidate in review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Aluminium adjuvants--in retrospect and prospect

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Crystal structure of the malaria vaccine candidate apical membrane antigen 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.055

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.08.055

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/18804135

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46135488&oldid=2094189600"